<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>SAAS</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>4dmedical raises $105M to bolster U.S. CT:VQ lead</title>
      <description>
        <![CDATA[Australian respiratory imaging technology company 4dmedical Ltd. raised AU$150 million (US$105 million) in an institutional placement to accelerate U.S. adoption of its CT:VQ lung imaging software to bolster the company’s lead in software-based lung imaging.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728274</guid>
      <pubDate>Thu, 29 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728274-4dmedical-raises-105m-to-bolster-us-ct-vq-lead</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2026/4DMedical_Respiratory_Imaging-29jan26.webp?t=1769717388" type="image/jpeg" medium="image" fileSize="80582">
        <media:title type="plain">4DMedical Respiratory Imaging</media:title>
        <media:description type="plain">Melbourne-headquartered 4dmedical is advancing its respiratory imaging technology and expanding the U.S. rollout of its FDA-cleared CT:VQ software that measures ventilation and perfusion in the lungs. Credit: 4dmedical</media:description>
      </media:content>
    </item>
    <item>
      <title>Reset Moves to promote well-being in children with neurodivergence</title>
      <description>
        <![CDATA[Focused on promoting well-being amongst children with neurodivergence, Reset Moves Pty Ltd. created app-based games to help children not only focus with greater clarity, but also to better help them re-engage in certain settings.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721111</guid>
      <pubDate>Mon, 16 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721111-reset-moves-to-promote-well-being-in-children-with-neurodivergence</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Reset-moves-action-shot-2-16june25.webp?t=1750107418" type="image/jpeg" medium="image" fileSize="305012">
        <media:title type="plain">Reset Moves action shot</media:title>
        <media:description type="plain">Keeping kids active is one of Reset Moves’ priorities. Credit: Reset Moves</media:description>
      </media:content>
    </item>
    <item>
      <title>LVIS launches Neuromatch Access in US, Korea as EEG diagnostic</title>
      <description>
        <![CDATA[Standing for live visualization of brain circuits, LVIS Corp launched the cloud-based Neuromatch Access platform as a software as a service to help neurologists and medical professionals review, interpret and analyze electroencephalogram (EEG) data.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716162</guid>
      <pubDate>Wed, 22 Jan 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716162-lvis-launches-neuromatch-access-in-us-korea-as-eeg-diagnostic</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/LVIS-Neuromatch-Access-1-21.webp?t=1737582763" type="image/jpeg" medium="image" fileSize="195015">
        <media:title type="plain">Neuromatch Access</media:title>
        <media:description type="plain">The Neuromatch Access platform by LVIS helps analyze EEG data.</media:description>
      </media:content>
    </item>
    <item>
      <title>Bioage tumbles as safety issues halt phase II obesity study</title>
      <description>
        <![CDATA[Less than three months after going public via a $227.7 million IPO, shares of Bioage Labs Inc. (NASDAQ:BIOA) took a hit Dec. 9, losing 77% of their value, as safety concerns prompted the company to halt its phase II trial testing oral obesity candidate azelaprag. The Strides study, launched in July, had been testing azelaprag, an oral apelin receptor agonist licensed from Amgen Inc., as a monotherapy and in combination with GLP-1/GIP therapy Zepbound (tirzepatide, Eli Lilly and Co.) in obesity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715154</guid>
      <pubDate>Mon, 09 Dec 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715154-bioage-tumbles-as-safety-issues-halt-phase-ii-obesity-study</link>
    </item>
    <item>
      <title>Helfie AI partners with Microsoft to democratize health care</title>
      <description>
        <![CDATA[Mobile health platform company Helfie AI has partnered with Microsoft to offer Microsoft enterprise customers the ability to license Helfie’s cutting-edge health assessment tools directly through the Microsoft Azure Marketplace.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713750</guid>
      <pubDate>Wed, 30 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713750-helfie-ai-partners-with-microsoft-to-democratize-health-care</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Helfie-skin-cancer-30aug24.webp?t=1730322803" type="image/jpeg" medium="image" fileSize="222643">
        <media:title type="plain">Helfie skin cancer</media:title>
        <media:description type="plain">Helfie Skin AI checks for skin cancer. credit: Helfie AI</media:description>
      </media:content>
    </item>
    <item>
      <title> Genetic Technologies’ Genetype test detects early risk for multiple diseases</title>
      <description>
        <![CDATA[Nearly 80% of people in Australia and the U.S. that used Genetic Technologies Ltd.’s Genetype multi-risk assessment test showed an elevated risk for at least one disease covered by the test.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709797</guid>
      <pubDate>Fri, 05 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709797-genetic-technologies-genetype-test-detects-early-risk-for-multiple-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/GeneType-test-5july24.webp?t=1720210696" type="image/jpeg" medium="image" fileSize="63556">
        <media:title type="plain">GeneType-test</media:title>
        <media:description type="plain">Genetic Technologies Ltd. Genetype multi-risk assessment test. Credit: Genetic Technologies Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Sonio raises $5M to develop AI platform for fetal ultrasound diagnostics</title>
      <description>
        <![CDATA[Sonio SAS raised just over $5 million in its seed round to develop artificial intelligence (AI) software allowing health care professionals to determine the most appropriate pregnancy care. Its Sonio Diagnostic software delivers decision support for fetal ultrasound used in antenatal diagnostics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/520667</guid>
      <pubDate>Tue, 12 Jul 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/520667-sonio-raises-5m-to-develop-ai-platform-for-fetal-ultrasound-diagnostics</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/07-12-Sonio-Ecran.webp?t=1657660197" type="image/png" medium="image" fileSize="1594526">
        <media:title type="plain">Technician conducting fetal ultrasound </media:title>
        <media:description type="plain">Sonio Diagnostics is counting on vast ultrasound, genetic and biological databases to optimize antenatal diagnostics. Copyright: Sonio SAS</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA gives green light to Resapp’s sleep apnea 510(k) app</title>
      <description>
        <![CDATA[The U.S. FDA has given Resapp Health Ltd. the green light for its 510(k) Sleepcheckrx app to detect moderate to severe sleep apnea in adults as a prescription-only software-as-a-medical device. The FDA cleared the app as a class II medical device. Brisbane, Australia-based Resapp submitted the 510(k) premarket notification to the FDA in November 2021 for Sleepcheckrx for at-home sleep apnea screening.]]>
      </description>
      <guid>http://www.bioworld.com/articles/520600</guid>
      <pubDate>Fri, 08 Jul 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/520600-fda-gives-green-light-to-resapps-sleep-apnea-510k-app</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sleep-disorders/Sleep-phone-digital-health-mobile-app.webp?t=1745267246" type="image/jpeg" medium="image" fileSize="124975">
        <media:title type="plain">Smartphone on nightstand, woman sleeping in bed</media:title>
      </media:content>
    </item>
    <item>
      <title>Resmed to pay $1B for software provider Medifox Dan</title>
      <description>
        <![CDATA[Resmed Inc. has entered into a definitive agreement to acquire Medifox Dan GmbH, a German developer of out-of-hospital software solutions for providers in major settings across the care continuum, from software and services investor Hg. The deal – valued at roughly $1 billion – is expected to close by the end of the year, which is the end of the second quarter of Resmed’s 2023 fiscal year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/519763</guid>
      <pubDate>Thu, 16 Jun 2022 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519763-resmed-to-pay-1b-for-software-provider-medifox-dan</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deals-handshake-analysis-illustration.webp?t=1614643337" type="image/png" medium="image" fileSize="1213840">
        <media:title type="plain">Concept of business partnership</media:title>
      </media:content>
    </item>
    <item>
      <title>Artrya lists on ASX in AU$40M IPO to advance coronary artery disease AI software</title>
      <description>
        <![CDATA[PERTH, Australia – Medtech newcomer Artrya Ltd. listed on the Australian Securities Exchange (ASX) in an AU$40 million (US$28.6 million) initial public offering to commercialize its software that analyzes heart computed tomography (CT) scans via artificial intelligence (AI) to better diagnose coronary artery disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513843</guid>
      <pubDate>Tue, 30 Nov 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/513843-artrya-lists-on-asx-in-au40m-ipo-to-advance-coronary-artery-disease-ai-software</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/11-30-Artrya-co-founders-John-Barrington-John-Konstantopoulos.webp?t=1638312402" type="image/png" medium="image" fileSize="456297">
        <media:title type="plain">Artrya co-founders pose with bell, ASX backdrop</media:title>
        <media:description type="plain">John Barrington (left), co-founder and CEO, and John Konstantopoulos (right), co-founder and executive director, product. Credit: Artrya Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Flush with new funding, 4dmedical begins commercial trek to U.S.</title>
      <description>
        <![CDATA[PERTH, Australia &ndash; With a fresh injection of A$28.9 million (US$22.4 million) in grant funding from the Australian government and a capital raise of A$40 million, 4dmedical Ltd. is well on its way to commercializing its first lung imaging product in the U.S. and Australia. 4dmedical&rsquo;s X-ray velocimetry (XV) technology is the first FDA-cleared respiratory imaging solution that uses mathematical models and algorithms to convert sequences of X-ray images into four-dimensional quantitative data.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505019</guid>
      <pubDate>Mon, 22 Mar 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505019-flush-with-new-funding-4dmedical-begins-commercial-trek-to-us</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/03-22-4D-Medical-scan.webp?t=1616444930" type="image/png" medium="image" fileSize="964269">
        <media:title type="plain">Doctor holding tablet with 4dmedical software</media:title>
        <media:description type="plain">Lung Ventilation Analysis Software. Credit: 4dmedical Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Volpara acquires breast cancer risk assessment company CRA Health for $22M</title>
      <description>
        <![CDATA[PERTH, Australia &ndash; Wellington, New Zealand-headquartered Volpara Health Technologies Ltd. has acquired Boston-based CRA Health LLC for $18 million up front and an additional $4 million to be paid over the next 18 months in earnouts. Volpara&rsquo;s digital health solutions use imaging and artificial intelligence (AI) for early detection of breast cancer. The company&rsquo;s clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement and patient tracking.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503232</guid>
      <pubDate>Thu, 04 Feb 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503232-volpara-acquires-breast-cancer-risk-assessment-company-cra-health-for-22m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Merger-puzzle-pieces-arrow-hands.webp?t=1644441920" type="image/png" medium="image" fileSize="99873">
        <media:title type="plain">Hands holding arrow-shaped puzzle pieces</media:title>
      </media:content>
    </item>
    <item>
      <title>Generex establishes joint venture with Worldwide Digitech</title>
      <description>
        <![CDATA[Generex Biotechnology Corp.&rsquo;s wholly owned subsidiary Nugenerex Health partnered with Worldwide Digitech (WWDT) LLC to create a 50/50 joint venture, Nugenhealth LLC. The new company will draw on WWDT&rsquo;s software to develop an end-to-end software-as-a-service (SaaS) solution for chronic care management using remote patient monitoring.]]>
      </description>
      <guid>http://www.bioworld.com/articles/497151</guid>
      <pubDate>Fri, 28 Aug 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/497151-generex-establishes-joint-venture-with-worldwide-digitech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Merger-arrows-black-white.webp?t=1588276844" type="image/png" medium="image" fileSize="12462">
        <media:title type="plain">Black and white arrows merging into one</media:title>
      </media:content>
    </item>
    <item>
      <title>Brightinsight gets $40M series B to supply the back-end of digital health for pharma, med tech</title>
      <description>
        <![CDATA[Startup Brightinsight Inc. is working to make the infrastructure behind digital health easily accessible to pharma and med-tech companies. To aid it on this path, the San Jose, Calif.-based company has raised a $40 million series B round to expand its capabilities and global reach.]]>
      </description>
      <guid>http://www.bioworld.com/articles/436065</guid>
      <pubDate>Thu, 25 Jun 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436065-brightinsight-gets-40m-series-b-to-supply-the-back-end-of-digital-health-for-pharma-med-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/AI-digital-dollar-coins.webp?t=1588782231" type="image/png" medium="image" fileSize="299797">
        <media:title type="plain">Wireframe hands, coins</media:title>
      </media:content>
    </item>
    <item>
      <title>Web-based tool facilitates new antibiotic development</title>
      <description>
        <![CDATA[A new web-based tool allowing rapid <em>in silico</em> prediction of the ability of candidate antibiotics to accumulate in Gram-negative bacteria should enable subsequent prioritization of new compounds for synthesis and further evaluation, U.S. researchers reported Nov. 18, 2019, in <em> Nature Microbiology</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/431448</guid>
      <pubDate>Wed, 27 Nov 2019 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/431448-web-based-tool-facilitates-new-antibiotic-development</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibiotics-petri-dish.webp?t=1588349786" type="image/png" medium="image" fileSize="499611">
        <media:title type="plain">Petri dish and capsules</media:title>
      </media:content>
    </item>
    <item>
      <title>Genomics-focused Pieriandx closes $27M series B</title>
      <description>
        <![CDATA[St. Louis-based <a href="https://www.cortellis.com/intelligence/qsearch/Pieriandx" target="_blank">Pieriandx</a>, a clinical genomics informatics company, reported that it has closed a $27 million series B funding round led by Atw Partners and Sjf Ventures. Pieriandx provides a software-as-a-service platform that the company says permits the practice of clinical genomics as a standard of care.]]>
      </description>
      <guid>http://www.bioworld.com/articles/430685</guid>
      <pubDate>Tue, 29 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430685-genomics-focused-pieriandx-closes-27m-series-b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/DNA-NGS-genome-sequencing.webp?t=1588871366" type="image/png" medium="image" fileSize="527937">
        <media:title type="plain">DNA NGS genome sequencing</media:title>
      </media:content>
    </item>
    <item>
      <title>Resmed shines in Q1 as revenues jump 16%</title>
      <description>
        <![CDATA[It was a standout quarter for San Diego-based <a href="https://www.cortellis.com/intelligence/qsearch/Resmed" target="_blank">Resmed Inc</a>., which saw revenues jump to $681.1 million, with the U.S., Canada and Latin America serving as bright spots. "We have started fiscal year 2020 right where we left off with 2019," Michael Farrell, Resmed's CEO, said during a call on the results. "Our team achieved another quarter of the balanced growth across the portfolio, driven by continued strong performance in the mask category."]]>
      </description>
      <guid>http://www.bioworld.com/articles/430671</guid>
      <pubDate>Mon, 28 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430671-resmed-shines-in-q1-as-revenues-jump-16</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2019/Resmed-AirFit-F30-10-28.webp?t=1572576055" type="image/png" medium="image" fileSize="632851">
        <media:title type="plain">Resmed-AirFit-F30-10-28.png</media:title>
        <media:description type="plain">Airfit F30 CPAP mask. Credit: Resmed Inc.</media:description>
      </media:content>
    </item>
  </channel>
</rss>
